Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
Abstract Juvenile myelomonocytic leukemia (JMML) treatment primarily relies on hematopoietic stem cell transplantation and results in long-term overall survival of 50–60%, demonstrating a need to develop novel treatments. Dysregulation of the non-coding RNA transcriptome has been demonstrated before...
Guardado en:
Autores principales: | Mattias Hofmans, Tim Lammens, Barbara Depreter, Ying Wu, Miriam Erlacher, Aurélie Caye, Hélène Cavé, Christian Flotho, Valerie de Haas, Charlotte M. Niemeyer, Jan Stary, Filip Van Nieuwerburgh, Dieter Deforce, Wouter Van Loocke, Pieter Van Vlierberghe, Jan Philippé, Barbara De Moerloose |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0585c9174d894b83a10e9c9210ba9f53 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
por: Daniel B. Lipka, et al.
Publicado: (2017) -
Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing
por: Annelynn Wallaert, et al.
Publicado: (2017) -
Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia
por: Elliot Stieglitz, et al.
Publicado: (2017) -
JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
por: Yunus Murat Akcabelen, et al.
Publicado: (2021) -
The Small RNA ncS35 Regulates Growth in <named-content content-type="genus-species">Burkholderia cenocepacia</named-content> J2315
por: Sanne Kiekens, et al.
Publicado: (2018)